# GlaxoSmithKline

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/glaxosmithkline/

## Facts

| Field | Value |
| --- | --- |
| Country | GB |
| Description | British multinational pharmaceutical and biotechnology company |
| OpenAlex ID | https://openalex.org/F4320307773 |
| ROR ID | https://ror.org/01xsqw823 |
| Works | 42,273 |

## Funder papers

Showing 15 of 41.

- [Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes](https://scholariq.org/papers/intensive-blood-glucose-control-and-vascular-outcomes-in-patients-with-type-2/)
- [Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes](https://scholariq.org/papers/glucose-control-and-vascular-complications-in-veterans-with-type-2-diabetes/)
- [Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer](https://scholariq.org/papers/niraparib-in-patients-with-newly-diagnosed-advanced-ovarian-cancer/)
- [Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases](https://scholariq.org/papers/executive-summary-of-the-kdigo-2021-guideline-for-the-management-of-glomerular/)
- [Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial](https://scholariq.org/papers/safety-and-tolerability-of-the-novel-non-steroidal-mineralocorticoid-receptor/)
- [Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction](https://scholariq.org/papers/efficacy-of-dapagliflozin-on-renal-function-and-outcomes-in-patients-with-heart/)
- [Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups](https://scholariq.org/papers/canagliflozin-and-cardiovascular-and-renal-outcomes-in-type-2-diabetes-mellitus/)
- [Lupus nephritis: clinical presentations and outcomes in the 21st century](https://scholariq.org/papers/lupus-nephritis-clinical-presentations-and-outcomes-in-the-21st-century/)
- [Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial](https://scholariq.org/papers/long-term-kidney-outcomes-of-semaglutide-in-obesity-and-cardiovascular-disease/)
- [Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF](https://scholariq.org/papers/initial-decline-dip-in-estimated-glomerular-filtration-rate-after-initiation-of/)
- [KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)](https://scholariq.org/papers/kdigo-2025-clinical-practice-guideline-for-the-management-of-immunoglobulin-a/)
- [KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary](https://scholariq.org/papers/kdigo-2025-clinical-practice-guideline-for-the-evaluation-management-and/)
- [Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers](https://scholariq.org/papers/molecular-biomarkers-of-disease-outcomes-and-mechanisms-of-acquired-resistance/)
- [Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease](https://scholariq.org/papers/efficacy-and-safety-of-spironolactone-in-patients-with-hfpef-and-chronic-kidney/)
- [Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD](https://scholariq.org/papers/correlates-and-consequences-of-an-acute-change-in-egfr-in-response-to-the-sglt2/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.